Summary
• Cardlytics, Inc. shares rose 5.8% to $1.10 in after-hours trading without clear catalysts.
• The company reported a significant earnings surprise for Q3 2025 but faces a 74% decline in stock value year-to-date.
• Analysts generally maintain a “Hold” rating as market activity appears routine amid ongoing operational challenges.
Cardlytics, Inc. (NASDAQ: CDLX) saw its shares rise to $1.10 in after-hours trading, an increase of 5.8% from the last close of $1.04. This uptick occurred amid routine trading without any clear catalyst to explain the momentum.
Earnings Report Lingers in the Background
Investors may be reflecting on the company’s recent earnings results released on November 5, 2025. Cardlytics reported a significant earnings surprise with actual earnings of -$1.36 per share versus a consensus estimate of -$0.15, marking a 806% surprise. CEO Amit Gupta remarked on the company’s strategic refocus to improve financial health and work towards a path of growth, emphasizing their commitment to enhancing operational discipline.
Despite the impressive earnings surprise, the stock continues to face considerable challenges, with a yearly performance showing a drop of approximately 74%.
[chart type=’income-bar-chart’ value=’CDLX’]
Market Performance Overview
In recent performance metrics, Cardlytics has experienced substantial declines across several timeframes. The stock is currently trading down 74%, year-to-date, and has registered -44.7% over the previous half year. The average trading volume over the last 10 days stands at 625,966, significantly lower than the 3-month average of 4,856,212, indicating reduced market activity.
[chart type=’performance’ value=’CDLX’]
Trading Setup: Volatility and Technical Analysis
Looking at the technical indicators, the stock shows a 14-day Relative Strength Index (RSI) of 35.7, suggesting it could be broadly undervalued but also signaling bearish momentum. The Average True Range (ATR) indicates volatility at 0.12, highlighting typical price fluctuation in recent sessions.
Moving averages depict a challenging trend: the stock is underperforming against the 20-day, 50-day, and 200-day simple moving averages, with deviations of -11.1%, -34.8%, and -40.0%, respectively.
[chart type=’price’ value=’CDLX’]
Analyst Sentiment and Outlook
Currently, analysts maintain a “Hold” rating for Cardlytics. While no fresh ratings updates have emerged recently, the sentiment reflects a cautious approach among stock watchers. Investors may continue to monitor any potential changes in guidance or strategic direction from the company as it strives to stabilize its operations.
With trading reflecting recent earnings perspectives, the stock is gaining attention as traders evaluate market conditions moving forward. With no fresh catalyst in play, the move reflects routine market activity as participants evaluate short-term positioning.